Fospropofol
- Generic Name
- Fospropofol
- Drug Type
- Small Molecule
- Chemical Formula
- C13H21O5P
- CAS Number
- 258516-89-1
- Unique Ingredient Identifier
- LZ257RZP7K
- Background
Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent. Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008.
Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act.
- Indication
For monitored anaesthesia care sedation in patients undergoing diagnostic procedures like bronchoscopy and colonscopy or minor surgical procedures like arthroscopy and bunionectomy.
- Associated Therapies
- Monitored anesthesia care sedation
AbbVie's Vyalev for Parkinson's Disease Incorporates Key Innovations from KU Chemist
• Vyalev, a new subcutaneous drug therapy by AbbVie for Parkinson's disease, has been approved by the FDA in October 2024 after successful Phase 3 trials.
• The therapy uses a wearable pump to deliver levodopa/carbidopa, providing consistent dosage and reducing motor fluctuations in Parkinson's patients.
• University of Kansas chemist Valentino Stella contributed to the drug's development by discovering forms of L-dopa and carbidopa suitable for infusion.
• Clinical trials showed Vyalev significantly increased 'on' time (optimal motor control) and decreased 'off' time (return of symptoms) compared to oral treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath